Results 221 to 230 of about 368,793 (264)

The impact of left ventricular assist devices on kidney function: a systematic review and meta-analysis. [PDF]

Egypt Heart J
Hosseini A, Darouei B, Amani-Beni R, Shafie D, Mazaheri-Tehrani S, Haghighatpanah MA, Heidarpour M, Amini-Salehi E, Hashemi SM, Harrison A, Hameed I, Reid CM, Movahed MR.   +12 more
europepmc   +1 more source

Mechanism of afatinib resistance in non-small cell lung cancer patients with nonclassical EGFR mutations: A multicenter, retrospective study. [PDF]

Medicine (Baltimore)
Wu R, Fang S, Zhang Y, Zhou T, Yin J, Yao Y, Ding M, Ding H, Wang J, Zhang Q, Liu H.   +10 more
europepmc   +1 more source

Sunvozertinib in EGFR Exon 20 Insertion NSCLC: Approved but Not Available - Practical Dose Selection Considerations and Real-World Access Challenges. [PDF]

Lung Cancer (Auckl)
Aldecoa KAT, Arter ZL, Ou SI, Nagasaka M.   +3 more
europepmc   +1 more source

Effect of prior anti-EGFR therapy and baseline ctDNA profiling on the efficacy of pertuzumab plus trastuzumab in HER2-amplified metastatic colorectal cancer: an integrated analysis of TRIUMPH/MyPathway. [PDF]

ESMO Open
Matsubara Y, Wakabayashi M, Okamoto W, Kato T, Esaki T, Kato K, Komatsu Y, Masuishi T, Nishina T, Bando H, Misumi T, Fukui M, Matsuda S, Ikeda Y, Malato J, Schulze K, Price R, Sato A, Yoshino T, Nakamura Y.   +19 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

EGFR and anti-EGFR nanobodies: review and update

Journal of Drug Targeting, 2020
Targeted therapy is one of the favourable methods used in cancer treatment. Several recombinant proteins and small-molecules used for this aim include monoclonal antibodies, antibody fragments and peptides. Nanobody (Nb) is a camelid antibody fragment that is very effective in targeted therapy.
Jafar Sharifi, Mohammad Reza Khirehgesh, Fatemeh Safari, Bahman Akbari   +3 more
openaire   +2 more sources

EGFR Aggregation in the Brain

ACS Chemical Neuroscience, 2021
Recent findings showed that preformed fibrils (PFFs) of misfolded proteins, including α-synuclein (α-syn) and amyloid-β (Aβ), activate EGFR in cell cultures and animal models of amyloid propagation. Comparing these supramolecular structures to normal EGFR ligands such as EGF and HB-EGF suggests that these PFFs might trigger the formation of high order ...
Omid Tavassoly, Iman Tavassoly
openaire   +2 more sources

Clonal dominance of EGFR and efficacy of EGFR-tyrosine kinase inhibitors (EGFR-TKIs) in NSCLC.

Journal of Clinical Oncology, 2020
e21501 Background: Though EGFR mutations in lung cancer are identified most often on the trunks of tumor phylogenetic trees in early stage, whether EGFR would always be the dominant clone in the advanced stage is unknown, as cancer evolution often follows a branched trajectory, with divergent subclones evolving simultaneously.
Xinghao Ai, Rongrong Chen, Jiuwei Cui, Jiexia Zhang, Wen Lin, Congying Xie, Xiaohua HU, Junping Zhang, Xiaodong Jiao, Chuangzhou Rao, Weihua Yang, Lianpeng Chang, Xuefeng Xia, Xin Yi, Shun Lu   +14 more
openaire   +1 more source